Skip to content

Effect of 12-week FW Programme on Sex Hormone Levels and Risk Factors for MS in Postmenopausal Women

Effect of 12-week Fitness Walking Programme on Sex Hormone Levels and Risk Factors for Metabolic Syndrome in Postmenopausal Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06454032
Enrollment
30
Registered
2024-06-12
Start date
2022-04-16
Completion date
2022-12-30
Last updated
2024-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopause Women

Keywords

Exercise, Postmenopause, Women's health, Metabolism, Sex hormone

Brief summary

Postmenopausal women were separated into two groups: one participating in a 12-week fitness walking programe as the fitness walking group, and the other maintaining their regular lifestyle as the control group. The study evaluated alterations in health markers and examined the correlation between metabolic syndrome risk factors and sex hormone levels before and after the intervention.

Detailed description

According to the inclusion and exclusion criteria, our study invlved postmenopausal women aged from 50 to 69 years old. After the selection process, baseline assessments were conducted, including evaluations of metabolic syndrome risk factors, body morphology measurements, sex hormone levels, and cardiopulmonary exercise testing. Participants were then randomly assigned to either the fitness walking group or the control group using a random number table. Participants in the fitness walking group completed a 12-week fitness walking program, while those in the control group maintained their usual lifestyle without any intervention. During the post-intervention assessment, all baseline measurements were repeated to evaluate changes in the previously measured indicators.

Interventions

BEHAVIORALFitness walking

Fitness walking for 12 weeks.

BEHAVIORALMaintained lifestyle

Maintained their normal lifestyle, without exercise intervention.

Sponsors

Beijing Sport University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* (1) Participants were entirely voluntary and capable of completing the full 12-week intervention process. * (2) Participants were postmenopausal women aged between 50 and 69 years. * (3) Participants had been postmenopausal for over 12 months and had not received exogenous estrogen supplementation post-menopause.

Exclusion criteria

* (1) Participants had a history of acute or chronic musculoskeletal disorders, cardiovascular diseases, diabetes, or other conditions that might impact their ability to engage in the intervention. * (2) Participants had recent hormone treatment, anti-inflammatory medication use, or other medications affecting blood indices. * (3) Participants experienced unstable body weight (fluctuations exceeding 2.5 kg) in the past three months. * (4) Participants were concurrently enrolled in other intervention studies or maintained regular exercise routines. * (5) Participants had smoking or alcohol consumption habits.

Design outcomes

Primary

MeasureTime frameDescription
Systolic blood pressure (SBP)At the beginning-at 12 weeks.The change of SBP before and after intervention
Diastolic blood pressure (DBP)At the beginning-at 12 weeks.The change of DBP before and after intervention
Waist circumference (WC)At the beginning-at 12 weeks.The change of WC before and after intervention
Fasting blood glucose (FBG)At the beginning-at 12 weeks.The change of FBG before and after intervention
Triglycerides (TG)At the beginning-at 12 weeks.The change of TG before and after intervention
High-density lipoprotein cholesterol (HDL-C)At the beginning-at 12 weeks.The change of HDL-C before and after intervention

Secondary

MeasureTime frameDescription
HeightAt the beginning-at 12 weeks.The change of height before and after intervention
Oestradiol (E2)At the beginning-at 12 weeks.The change of E2 before and after intervention
Body mass index (BMI)At the beginning-at 12 weeks.The change of BMI before and after intervention
Testosterone (T)At the beginning-at 12 weeks.The change of T before and after intervention
Sex hormone-binding globulin (SHBG)At the beginning-at 12 weeks.The change of SHBG before and after intervention
Dehydroepiandrosterone sulphate (DHEA-S)At the beginning-at 12 weeks.The change of DHEA-S before and after intervention
Maximal oxygen uptake (VO2max)At the beginning-at 12 weeks.The change of VO2max before and after intervention
Body weight (BW)At the beginning-at 12 weeks.The change of BW before and after intervention

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026